Security readout for executives and security teams
Plain-English summary
This CVE affects Hospira Symbiq Infusion System 3.13 and earlier. A remote authenticated user with elevated privileges could trigger unspecified "unanticipated operations" through an incorrectly exposed function. The public record does not explain the clinical effect, severity, or fix, so organizations should first confirm whether any Symbiq pumps remain deployed or reachable.
Executive priority
Treat this as a healthcare technology exposure requiring prompt asset confirmation. Business urgency depends on whether affected infusion systems remain deployed and reachable; the supplied sources do not establish active exploitation or a quantified severity score.
Technical view
The issue is an incorrectly exposed function callable by remote authenticated users leveraging elevated privileges. The affected product is Hospira Symbiq Infusion System versions 3.13 and earlier. The CVE record does not provide CVSS, CWE, function details, impact boundaries, or patch information in the supplied bundle.
Likely exposure
Exposure is limited to environments that still operate Hospira Symbiq Infusion System 3.13 or earlier, especially where device management paths are network-reachable by authenticated users.
Exploitation context
The supplied sources do not show CISA KEV listing or active exploitation. The issue requires remote authentication and elevated privileges, but the records do not define the exact privilege level, access path, or operation triggered.
Researcher notes
The public bundle is sparse: no CVSS, CWE, patch details, function name, or clinical impact are provided. Analysis should stay anchored to authenticated privileged misuse of an exposed function on Symbiq 3.13 and earlier.
Mitigation direction
- Inventory Hospira Symbiq Infusion Systems and record software versions.
- Prioritize devices running version 3.13 or earlier for review.
- Check Hospira, FDA, or CISA ICS-CERT guidance for approved remediation.
- Restrict network access to device management interfaces where operationally feasible.
- Review privileged accounts with access to infusion system management functions.
Validation and detection
- Confirm whether any Symbiq Infusion Systems remain in production or storage.
- Verify firmware or software versions against the affected range.
- Review network segmentation around clinical device management networks.
- Check logs or access records for unexpected privileged remote activity.
- Document any compensating controls until vendor guidance is confirmed.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CVE-2015-3965 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Unknown
- CVSS
- Not scored
- Known Exploited
- No
- Published
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS and timeline data
No CVSS vectors or timeline events were available in the normalized CVE source material.
Source materials
- CVE List V5 sourceCVE List V5
- https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01CVE reference · x_refsource_MISC
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.